SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11965)5/22/2013 8:09:15 PM
From: LT2011  Read Replies (1) | Respond to of 13111
 
NTTG, thank you for what I believe was a fair and non bias opinion on your part. For those of us who lack the medical background I had to read your post multiple times in order to understand your thought process.

Based on your opinion from your previous point do you believe PVCT is going backwards, standing still or slowly making progress towards a phase 3 trial approval?

Lastly, based on your opinion do you believe that the phase 3 trial primary endpoints are obtainable?



To: NTTG who wrote (11965)5/23/2013 10:20:21 AM
From: Mammon1 Recommendation  Respond to of 13111
 
nttg. the definition of a moot point. [not mute] usingenglish.com
which is also the definition of your exposition on whether the bystander effect will be on the drug label.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News